Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Ingrezza treatment eases chorea regardless of sex, age: Trial data

Ingrezza (valbenazine), an approved treatment for chorea, or uncontrolled movements, related to Huntington’s disease, shows similar effectiveness among patients irrespective of factors like sex, age, or disease severity, according to a new analysis of data from a Phase 3 clinical trial. Moreover, a separate data analysis from…

HDSA 2024: Huntington’s disease clinical trials enrolling in US

Clinical trials testing either tominersen, an experimental therapy designed to target the underlying cause of Huntington’s disease, or dalzanemdor, an oral candidate that aims to improve cognitive abilities, are currently enrolling Huntington’s patients in the U.S. Updates on the therapies’ clinical programs were provided by representatives of their…

HDSA 2024: Community urged to participate in observational studies

The Huntington’s disease community was encouraged to step up and get involved in observational studies to help scientists better understand the neurodegenerative disorder and accelerate the development of potential treatments. Participating in research “is the greatest thing that we can do to help expedite treatments for HD [Huntington’s disease],”…

AMT-130 is first Huntington’s therapy to receive RMAT status

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to AMT-130, an experimental gene therapy for Huntington’s disease, the first time a Huntington’s treatment candidate has received such a designation. The RMAT designation is given to therapies that seek to treat, modify,…